Beta-Blockers in the Elderly

107 Pages·1982·5.057 MB·English

by  B. Åblad (auth.), Professor Dr. Erich Lang, Dr. Fritz Sörgel, Dr. Lothar Blaha (eds.)

Beta -Blockers
in the Elderly
Edited by
E. Lang F. Sorgel L. Blaha
With Contributions by
B. Ablad c.-J. Estler J. W. Franz M. Gastpar
L. Hansson 1. Herlitz A. Hjalmarson G. K. Krieglstein
F. W. Lohmann R. Rost B. Rurup J. Schulz
F. Sorgel A. Vedin F. Waagstein B. O. Williams
With 29 Figures and 17 Tables
Springer-Verlag
Berlin Heidelberg New York 1982
12. International Congress of Gerontology
Hamburg, July 12.-17., 1981
Satellite Symposion:
Beta-Blockers in the Elderly
Erlangen-Niirnberg, July 22.-24., 1981
Professor Dr. Erich Lang
Carl-Korth-Institut fUr Herz- Kreislauferkrankungen
Waldkrankenhaus St. Marien
Rathsberger Str. 57, 8520 Erlangen (Germany)
Dr. Fritz Sorgel
Institut fUr Rechtsmedizin, U niversitiit Erlangen-Niirnberg,
UniversitiitsstraJ3e 22, 8520 Erlangen (Germany)
Dr. Lothar Blaha
Universitiits-Nervenklinik, 8520 Erlangen (Germany)
ISBN-13 :978-3-540-11682-0 e-ISBN-13 :978-3-642-68674-0
DOl: 10.1007/978-3-642-68674-0
Library of Congress Cataloging in Publication Data.
Main entry under title: Beta-blockers in the elderly. Bibliography: p. Includes index.
1. Adrenergic beta receptor blockaders. 2. Geriatric pharmacology. I. Lang. E.
(Erich). 1935-[I. Ablad, B. (Bengt) [DNLM: I. Adrenergic beta receptor
blockaders. 2. Drug therapy - In old age.
QV 132 B5617] RM323.5.B4781982 615'.71 82-6004
ISBN-13 :978-3-540-11682-0 AACR2
This work is subject to copyrigh t. All rights are reserved, whether the whole or part
of the material is concerned, specifically those of translation, reprinting, re-use of il
lustrations, broadcasting, reproduction by photocopying machine or similar means,
and storage in data banks. Under § 54 of the German Copyright Law, where copies
are made for other than private use, a fee is payable to "Verwertungsgesellschaft
Wort", Munich.
( by Springer-Verlag Berlin Heidelberg 1982
The use of registered names, trademarks, etc. in this publication does not imply,
even in the absence of a specific statement: that such names are exempt from the
relevant protective laws and regulations and therefore free for general use.
2121/3140-543210
Preface
In conjunction with the Twelfth International Congress of
Gerontology, the Carl-Korth Institute for Cardiovascular
Research organized an international symposium on "Beta
Blockers in the Elderly." It was the intention of the Scientific
Committee that during this symposium we would discuss the
specific problems and therapeutic implications arising when
elderly people have to be treated with beta-blocking agents.
Special emphasis was placed on the side effects and the age
dependent features of beta-blocker therapy.
Beta-blockers have become established in the treatment of
both cardiovascular diseases and neuropsychiatric disorders.
Their effectiveness in patients suffering from coronary heart
disease, hypertension, and hyperkinetic cardiac syndromes
has long been proven. The development of new, selectively
active beta-blockers has substantially reduced the number of
possible side effects, thus enhancing therapeutic safety.
Because side effects cannot be eliminated, however, beta
blockers have been introduced only hesitantly into treatment
of the elderly.
This book is the first wide-ranging survey of the use of beta
blockers in elderly patients. The articles contained herein -
written by pharmacologists, cardiologists, sports physicians,
neurologists, psychiatrists, and ophthalmologists - show
that advanced age alone does not contraindicate the use of
beta-blockers and sympatholytic substances. Also provided
are guidelines for examination and determination of in
dications in the elderly.
Both the symposium and the publication of this volume have
been kindly supported by Astra Chemicals, West Germany.
E. Lang, Erlangen
v
Table of Contents
I. The Pharmacological Basis of fi-Blocking Agents
fi-Blockers: Theory, Action and Application to the
Elderly (B. Ablad) . . . . . . . . . . . . 3
Pharmacokinetics of fi-Blockers in the Elderly
(C.-J. Estler and F. Sorgel) . . . . . . . . . . . . 23
II. Clinical Aspects . . . . . . . . . . . . . . . . 33
Treatment of Hypertension with fi-Blockers in Elderly
Patients (L. Hansson). . . . . . . . . . . . .. 35
Mechanism of Action of Combined Treatment with
f3-Blockers and Diuretics in Elderly Hypertensive
Patients (B. O. Williams) . . . . . . . . . . . . . 41
Treatment of Myocardial Infarction with fi-Blockers
in Elderly Patients (A. Hjalmarson, 1. Herlitz, and
F. Waagstein) ............... " 47
Secondary Prevention Trials with fi-Blocking Drugs
After Myocardial Infarction (A. Vedin). . . . . . . 57
fi-Receptor Therapy of Cardiac Rhythm Disturbances in
Old Age (1. Schulz and B. Rurup) . . . . . . . . . 63
/II. Special Indications . . . . . . . . . . . . . . 69
Problems of Physical Activity During Treatment with
fi-Blockers (R. Rost) . . . . . . . . . . . . . . . 71
VII
Metabolic Effects of p-Blockers (F. W. Lohmann and
J. W. Franz). . . . . . . . . . . . . . . . . . . 83
The Role of p-Blockers in Psychiatry and Neurology
with Special Reference to Older Patients (M. Gastpar) 89
Indications for P-Blockers in Glaucoma Patients (G. K.
Krieglstein) . 97
Subject Index 105
VIII
List of Contributors
B. Ablad
Hassle Research Laboratories, AB Hassle, 431 83 Molndal,
Sweden
c.-1. Estler
Institut fUr Pharmakologie und Toxikologie, Lehrstuhl fUr
Toxikologie und Pharmakologie der Universitat Erlangen
Niirnberg, Universitatsstral3e 22, 8520 Erlangen, Federal
Republic of Germany
1. W. Franz
Abteilungen fUr Sportmedizin und Kardiologie, Freie Uni
versitat Berlin, 1000 Berlin, Federal Republic of Germany
M. Gastpar
Psychiatrische Universitatsklinik, Wilhelm-Klein-Stral3e 27,
4056 Basel, Switzerland
L. Hansson
Department of Medicine, astra Hospital, University of
Goteborg, 416 85 G6teborg, Sweden
1. Herlitz
Department of Medicine I, Sahlgren's Hospital, University of
G6teborg, 41685 G6teborg, Sweden
A. Hjalmarson
Department of Medicine I, Sahlgren's Hospital, University of
Goteborg, 41685 Goteborg, Sweden
G. K. Krieglstein
U niversitats-Augenklinik, J osef-Schneider-Stral3e 11,
8700 Wiirzburg, Federal Republic of Germany
IX
F. W. Lohmann
1. Innere Abteilung, Krankenhaus Neukolln, Rudower
StraBe 56, 1000 Berlin 47, Federal Republic of Germany
R. Rost
Institut fUr Kreislaufforschung und Sportmedizin, Deutsche
Sporthochschule, Carl-Diem-Weg, 5000 Koln 41, Federal
Republic of Germany
B.Riirup
1. Geriatrische Klinik des Geriatrischen Zentrums, SHidti
sches Klinikum Berlin-Buch, 1115 Berlin, German Democra
tic Republic
1. Schulz
1. Geriatrische Klinik des Geriatrischen Zentrums, SHidti
sches Klinikum Berlin-Buch, 1115 Berlin, German Democra
tic Republic
F. Sorgel
Institut fUr Rechtsmedizin, U niversitat Erlangen-N limberg,
UniversitatsstraBe 22, 8520 Erlangen, Federal Republic of
Germany
A. Vedin
Department of Medicine, Ostra Hospital, University of
Goteborg, 41685 Goteborg, Sweden
F. Waagstein
Department of Medicine I, Sahlgren's Hospital, University of
Goteborg, 41685 Goteborg, Sweden
B. W. Williams
University Department of Geriatric Medicine, Glasgow,
Scotland
x
I. The Pharmacological Basis
of [3-Blocking Agents
P-Blockers: Theory, Action, and Application
to the Elderly
8. Ablad
In 1948, Ahlquist [3] suggested that the adrenergic transmitter noradren
aline and adrenal medullary adrenaline elicit their effects by combining
with two kinds of receptors: rx and p. More recent studies have shown that
p-adrenoceptors are not homogeneous. Lands et al. [18] have suggested a
Pz·
subdivision into PI and Table 1 shows some adrenergic effects and the
type of receptor mainly involved in mediating each effect. rx-Receptors
mediate, for instance, contraction of smooth muscle in blood vessels and
uterus, while PI-receptors mediate cardiac stimulation and other effects
such as lipolysis and release of renin./fz-Receptors mediate smooth muscle
Table 1. Examples of adrenergic target organs, effects, and main types of mediating
adrenoceptor
Effector Type of Adrenergic
organ receptor effect
Heart Increased rate
Increased contractility
Increased conduction
Increased exitability
Increased automaticity
Blood
vessels :< Contraction
Ilz Dilatation
Bronchi Ilz Relaxation
Uterus ex Contraction
liz Relaxation
Skeletal
muscle fJz Tremor
Kidneys fJ, Renin release
Fat tissue (i, Lipolysis
Skeletal
muscle fJz Glycogenolysis
fJz K + transport into cells
Pancreas ex Inhibition of insulin release
liz Stimulation of insulin release
3